Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
|
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
  • [21] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] QUAlity of LIfe and survival of meTAStatic colorectal cancer patients treated with trifluridine-tipiracil (QUALITAS)
    Hamers, P.
    Vink, G.
    Elferink, M.
    Koopman, M.
    May, A. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S434 - S435
  • [23] Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)
    Hamers, Patricia A. H.
    Vink, Geraldine R.
    Elferink, Marloes A. G.
    Stellato, Rebecca K.
    Dijksterhuis, Willemieke P. M.
    Punt, Cornelis J. A.
    Koopman, Miriam
    May, Anne M.
    CLINICAL COLORECTAL CANCER, 2022, 21 (02) : 154 - 166
  • [24] Exploratory analysis of trifluridine/tipiracil in late-stage metastatic colorectal cancer (mCRC): Prognostic factors
    Karthaus, Meinolf
    Hoell, B.
    Zaun, G.
    Guyot, M.
    Schuler, Martin H.
    Kasper, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis
    Prejac, Juraj
    Omcen, Tomislav
    Radic, Jasna
    Vrdoljak, Eduard
    Frobe, Ana
    Plestina, Stjepko
    ONCOLOGY, 2024, 102 (03) : 217 - 227
  • [26] Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E381 - E383
  • [27] Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
    Malik, Mateusz
    Radecka, Barbara
    Gelej, Marek
    Jackowska, Aleksandra
    Filipczyk-Cisarz, Emilia
    Zurowska, Michalina
    Hetman, Katarzyna
    Foszczynska-Kloda, Malgorzata
    Kania-Zembaczynska, Beata
    Manka, Danuta
    Orlikowska, Marlena
    Bodnar, Lubomir
    BIOMEDICINES, 2024, 12 (09)
  • [28] Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil
    Colloca, G.
    Venturino, A.
    Guarneri, D.
    ANNALS OF ONCOLOGY, 2020, 31 (07) : 958 - 958
  • [29] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Martinez-Perez, Julia
    Carmen Riesco-Martinez, M.
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650
  • [30] Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Fukuoka, Shota
    Takashima, Atsuo
    Kumekawa, Yosuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Esaki, Taito
    Makiyama, Akitaka
    Denda, Tadamichi
    Satake, Hironaga
    Suto, Takeshi
    Sugimoto, Naotoshi
    Katsumata, Kenji
    Ishikawa, Toshiaki
    Kashiwada, Tomomi
    Oki, Eiji
    Komatsu, Yoshito
    Yoshimura, Kenichi
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)